Director Keyser D Jeffrey exercised 3,832 in-the-money shares at a strike of $3.13 (SEC Form 4)

$LTRN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $LTRN alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KEYSER D JEFFREY

(Last) (First) (Middle)
1920 MCKINNEY AVENUE, 7TH FLOOR

(Street)
DALLAS TX 75201

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Lantern Pharma Inc. [ LTRN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 07/24/2024 X(1) 3,832 A $3.13 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Warrants $3.13 07/24/2024 X(1) 3,832 07/25/2019 07/25/2024 Common Stock 3,832 $0.00 0 D
Explanation of Responses:
1. On July 24, 2024, the Reporting Person exercised a Series A Warrant to purchase 3,832 shares of common stock at an exercise price of $3.13 per share.
/s/ Donald Jeffrey Keyser 07/25/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $LTRN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LTRN

DatePrice TargetRatingAnalyst
3/11/2022$34.00 → $36.00Buy
HC Wainwright & Co.
11/2/2021$32.00 → $34.00Buy
HC Wainwright & Co.
10/7/2021$32.00Buy
HC Wainwright & Co.
More analyst ratings

$LTRN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

    Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting blood-brain barrier (BBB) permeability. The application received a favorable PCT search report indicating no significant prior art, substantially strengthening its path to approval. The technology has demonstrated to-date exceptional performance in predicting BBB permeability across a wide range of chemical compounds, processing up to 100,000 molecul

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

    Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced advancements in the application of its RADR® AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs). The global ADC market is projected to reach $30.4 billion by 2028, growing at a CAGR of 41.7%, with several recently approved ADCs achieving blockbuster status with annual sales exceeding $1 billion. Major biotech and pharmaceutical companies have recently completed ADC-focused acquisitions valued at over $10 billion, highlighting the sect

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

    Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung cancer cases in Taiwan occur in never-smokers. Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The enrollm

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LTRN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LTRN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LTRN
SEC Filings

See more

$LTRN
Leadership Updates

Live Leadership Updates

See more
  • Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

    DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LTRN
Financials

Live finance-specific insights

See more
  • Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

    Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for development. Preliminary patient data and clinical readouts for the Phase 2 LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in the initial 7 patient lead-in cohort, and additional patients continue to be enrolled in the US. The Harmonic™ Trial has been expanded to both Japan and Taiwan with an expected 10 sites in East Asia; 5 in each country where the population of never-smokers is 33 to 35 percent of new cases in NSCLC. Phase 1 clinical trials for both synthetic lethal drug candidates, LP-18

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

    Webcast to be held Thursday, November 7th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the third quarter ended September 30, 2024 and provide guidance on upcoming milestones, cl

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

    Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development. Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic™ Trial released showing an 86% clinical benefit rate in the initial 7 patient safety lead-in cohort. Issued a Certificate of Patent by the Japanese Patent Office directed to Lantern Pharma's drug candidate LP-284, including claims covering the new molecular entity. Phase 1 clinical trials for both synthetic lethal drug candidates, LP-184 and LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts enrolled and over 40 patients

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LTRN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more